 |
|
 |
|
 |
 |
 |
Anaeropharma has successfully completed closing of 700 million yen financing for its clinical trials. The investor – Innovation Network Corporation of Japan (INCJ) plans to continuously contribute to Anaeropharma’s future potential financing.
Anaeropharma Science, Inc. and Eisai Co., Ltd. have concluded an option agreement concerning APS001, a novel anticancer agent currently under development at Anaeropharma Science that utilizes characteristic features of Bifidobacterium longum, as well as an agreement concerning the discovery of novel anticancer agents that utilize Bifidobacterium as a drug delivery system.
Anaeropharma’s Technology was introduced on Nikkei Business Daily. November 30, 2009
Anaeropharma Science, Inc., ©2009- All rights reserved.
Subscribe RSS